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ABSTRACT
Background Chronic obstructive pulmonary disease
(COPD) is a heterogeneous disease whose assessment
and management have traditionally been based on the
severity of airﬂow limitation (forced expiratory volume in
1 s (FEV1)). Yet, it is now clear that FEV1 alone cannot
describe the complexity of the disease. In fact, the
recently released Global Initiative for Chronic Obstructive
Lung Disease (GOLD), 2011 revision has proposed a new
combined assessment method using three variables
(symptoms, airﬂow limitation and exacerbations).
Methods Here, we go one step further and propose
that in the near future physicians will need a ‘control
panel’ for the assessment and optimal management of
individual patients with complex diseases, including
COPD, that provides a path towards personalised
medicine.
Results We propose that such a ‘COPD control panel’
should include at least three different domains of the
disease: severity, activity and impact. Each of these
domains presents information on different ‘elements’ of
the disease with potential prognostic value and/or with
speciﬁc therapeutic requirements. All this information can
be easily incorporated into an ‘app’ for daily use in
clinical practice.
Conclusion We recognise that this preliminary proposal
needs debate, validation and evolution (eg, including
‘omics’ and molecular imaging information in the future),
but we hope that it may stimulate debate and research
in the ﬁeld.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
a heterogeneous disease with pulmonary and extra-
pulmonary manifestations.1 Until very recently its
diagnosis and assessment was based on the pres-
ence and severity of chronic airﬂow limitation
(forced expiratory volume in 1 s (FEV1)).2 Yet, the
relationship between FEV1 and clinically relevant
domains of the disease, such as symptoms, exercise
capacity, frequency of exacerbations or the pres-
ence of comorbidity, is poor or non-existent.1
Importantly, each of these domains is clinically
relevant because they can inﬂuence outcomes,
such as prognosis, signiﬁcantly and independently3
and may deserve speciﬁc therapeutic interventions.
Hence, proper clinical assessment of patients with
COPD must include domains other than FEV1.4
The recently released Global Initiative for Chronic
Obstructive Lung Disease (GOLD) strategy recog-
nises these limitations and proposes to combine
FEV1, the level of symptoms and the past history
of exacerbations to assess and manage patients
with COPD more comprehensively.5 This is an
important step forward but it should not be
viewed as the ﬁnal one because it is largely based
on expert opinion, and therefore, likely to be modi-
ﬁed by future research.
Here, we hypothesise that the future assessment
and management of patients with COPD will
have to consider other domains of the disease to
properly capture its complexity and to provide the
best possible care to individual patients, hence
moving the ﬁeld towards personalised medicine in
COPD. To do so, we propose that a ‘COPD control
panel’ will have to be designed and validated. In
this paper, we present the theoretical basis of this
approach; propose an initial version of such a
‘control panel’ that considers three domains of the
disease (severity, activity and impact of the
disease); and explore its potential application in
two hypothetical individual patients.
COPD AS A COMPLEX SYSTEM
A complex system is a collection of linked individ-
ual elements with so-called emerging properties
that cannot be attributed to each element consid-
ered separately.6 7 A plane (ﬁgure 1A) is a complex
system since it is formed by numerous linked ele-
ments (engines, wings, fuselage, tires, others) and
has one emerging property: ﬂying. Yet, none of the
individual elements of a plane can ﬂy it on its
own. Life, health and disease are emerging proper-
ties of an extremely complex system: the human
body. In this context, the emerging discipline of
systems/network medicine states that diseases
should be viewed (diagnosed and treated) as the
consequence of one or more biological networks in
the relevant organ that become disease perturbed
through genetic and/or environmental pathogenic
changes.8 9
To ﬂy the plane safely, pilots need a ‘control
panel’ (ﬁgure 1B) that allows them to visualise the
status of the relevant elements of the plane
(instruments) and the environmental conditions
that surround it to make the appropriate decisions.
We propose that, similarly to pilots, doctors caring
for patients with COPD (and likely other complex
diseases9) should have a ‘COPD control panel’ that
allows them to visualise the status of the relevant
domains of the disease (and the environment) to
make the appropriate therapeutic decisions. This is
exactly what a good clinician does: to integrate
information coming from diverse sources (clinical,
biological, radiological, etc) to make a proper diag-
nosis and determine the best therapy in each
patient. Thus, medicine has been ‘personalised’
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since its very beginnings. The challenge today is that the
volume and complexity of information that the clinician has to
integrate has increased in proportion to the complexity of the
disease and will increase exponentially in the future as a result
of high throughput technologies that will provide data on pro-
teomics, metabolomics and genomics, and others such as
molecular imaging. Thus a ‘COPD control panel’ is likely to be
important in the individualised management of this and other
complex diseases.
THE COPD CONTROL PANEL: A THREE-DOMAIN PROPOSAL
We propose that a COPD control panel could be constructed
using three disease domains (severity, activity and impact). Each
of these domains contains information on a number of elements
of the system (COPD) that provide complementary and relevant
information for the proper management of the individual
patient, either because of its prognostic implications and/or
requirement for speciﬁc therapeutic intervention (ﬁgure 2).
The severity of a given disease (including COPD) is inversely
proportional to the functional reserve left in the target organ.10
In COPD, FEV1 is a good estimate of that functional reserve,
although other physiological measurements such as the
inspiratory to total lung capacity ratio (IC/TLC),11 arterial
blood gases5 and exercise capacity11 provide complementary
information that also reﬂect the severity of COPD, and import-
antly, may require speciﬁc therapeutic interventions (broncho-
dilator treatment/lung volume reduction surgery, oxygen
therapy or rehabilitation, respectively). Hence, we propose that
the ‘severity’ module of the COPD control panel includes infor-
mation on FEV1, IC/TLC, arterial oxygenation and exercise cap-
acity. We also propose to include the number and severity of
the comorbidities because of their well known prognostic
impact and need for speciﬁc therapy.3 The Charlson index12
may be a good indicator of comorbidities to be included in the
severity domain, but individual comorbidities present in COPD
(cardiovascular disease, metabolic syndrome, and depression,
etc) would be an alternative.13
The activity of a disease reﬂects the intensity of the bio-
logical mechanisms that cause it.10 14 The concept of ‘activity
of COPD’ has been ignored until now.15 Importantly activity
and severity do not always run in parallel. For instance, activity
may be high in the early stages of COPD but severity is mild.
By contrast, advanced disease may be severe but may have low
disease activity due to the spontaneous and/or therapeutically
Figure 1 A plane (A) is a complex
system and ﬂying is an emerging
property of the system. To ﬂy the
plane, the pilot in the cockpit (B) uses
a control panel formed by different
modules that inform them of the
functioning of the system and the
environment.
Figure 2 Proposal for a chronic obstructive pulmonary disease control panel. For further explanation, see text. 6MWD, 6 min walk distance; CAT,
Chronic Obstructive Pulmonary Disease Assessment Test; FEV1, forced expiratory volume in 1 s; IC/TLC, inspiratory to total lung capacity ratio;
mMRC, modiﬁed Medical Research Council Dyspnea Scale; PaO2, arterial oxygen pressure.
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induced downregulation of the biological mechanisms that
caused it. The most appropriate marker of activity in COPD is
an unresolved issue15 but several clinical and biological candi-
dates may be considered. Among the former, the rate of decline
of FEV1 is an obvious one since recent research has shown that
the rate of change in FEV1 among patients with COPD is
highly variable.16–18 Given that smoking is the major patho-
genic mechanism in the development of COPD, continued
smoking may also be considered a marker of disease activity.
Another potential clinical marker of disease activity may be the
frequency of exacerbations since, although they tend to increase
in patients with more severe disease, the frequent exacerbator
phenotype can also occur in moderate disease.19 Among poten-
tial biological markers of disease activity, recent research has
shown that the persistence of systemic inﬂammation (as indi-
cated by circulating leukocytes, C-reactive protein, interleukin-6
and/or ﬁbrinogen) is associated with increased mortality and
exacerbation rate,20 and that the addition of similar biomarkers
improves the ability of established clinical variables to predict
mortality in COPD.21 Finally, it is well known that uninten-
tional weight loss is also associated with poor prognosis in
COPD,22 although the persistence of systemic inﬂammation
alluded to above appears to be associated with an increased
body mass index (BMI).20 Hence we propose that the activity
domain of the COPD control panel includes information on
smoking status, FEV1 decline, annual rate of exacerbation, BMI
and selected systemic biomarkers.
The impact of any disease depends on how the patient per-
ceives the disease and modiﬁes his/her activities of daily living.
This perception is likely to vary substantially between indivi-
duals, as it is well established in asthma.23 In COPD, we have
traditionally assumed that mild disease (as assessed by FEV1)
has a minor impact on the patient, whereas the impact is
much greater in severe disease. Yet, instruments that measure
such an impact, like the St George’s Respiratory
Questionnaire24 and the COPD Assessment Test (CAT),25 have
shown that the relationship between FEV1 and health status is
poor and individual variability is enormous.1 In fact, as dis-
cussed above, the new GOLD 2011 recommendations recognise
this variability and propose to determine the level of symptoms
as a key component of the assessment of these patients.5
Similar arguments can be applied to other domains of the
disease, such as exacerbations,19 since a number of patients
suffer ‘unreported exacerbations’26 and lung function is severely
impaired in a subgroup of patients who had never required hos-
pitalisation because of exacerbation.27 These observations
suggest that, as described in asthma,23 28 there may be poor
symptom perceivers among patients with COPD. Finally, it is
of note that daily activities are impaired in some, but not all,
patients with COPD,29 and that objectively measured physical
activity is the strongest predictor of all-cause mortality in
patients with COPD.30 Hence, we propose that the impact
domain of the COPD control panel includes some symptom
measures (modiﬁed Medical Research Council Dyspnea Scale
(mMRC) and/or CAT) as well as the level of daily activity.
In summary, we propose that such a ‘COPD control panel’
provides a way to visualise the complexity of COPD, and that
the combined assessment of the severity, impact and activity
can best inform the physician on the most appropriate manage-
ment strategies for an individual patient.5 Yet, we acknowledge
that our proposal has limitations. For instance, the type of
measures included in each domain needs to be discussed and
validated, and how to link this type of holistic information to
speciﬁc therapeutic interventions needs to be determined.
TOWARDS PERSONALISED MEDICINE IN COPD
The practice of medicine was originally based largely on per-
sonal experience. It was only in the late 1980s when evidence-
based medicine (EBM) was introduced.31 EBM has facilitated
the development and reﬁnement of clinical practice guidelines32
but has well recognised limitations. The clearest one is that
randomised clinical trials, the cornerstone of EBM, study a
subset of the whole population of patients, and as a result, a
signiﬁcant degree of extrapolation is needed. Besides, they do
not take into account the individual phenotypic variation that
occurs inevitably in any disease. Thus only recommendations
for the general population of patients can be formulated. As a
result of these limitations, there is increasing interest in study-
ing well identiﬁed subgroups, so-called ‘clinical phenotypes’ of
patients who are associated with different outcomes and/or
deserve speciﬁc therapeutic interventions.33 This is not yet ‘per-
sonalised’ medicine (perhaps ‘stratiﬁed’ medicine), but it is
clearly a step forward in this direction.34 In this setting, two
hypothetical patients may illustrate the potential practical use
of the COPD control panel.
Patient A has mild disease (GOLD grade II, no hyperinﬂation,
normal arterial oxygen pressure, normal exercise tolerance and
no comorbidities), low impact (normal mMRC and CAT scores,
normal daily activity) but a high level of disease activity
(current smoker, increased FEV1 decline with two exacerbations
over the past 8 months plus raised levels of a potential bio-
marker of disease activity). Despite the ‘mild’ clinical presenta-
tion, the evidence of increased disease activity may indicate
the need for a therapeutic intervention (anti-inﬂammatory
therapy?) that prevents future progression of the disease.
By contrast, patient B is characterised by severe disease
(FEV1<50% predicted, hyperinﬂation, low exercise capacity,
comorbidities (cardiovascular disease and obesity)) and high
impact (high mMRC, low CAT, house bound). Yet, there is
little evidence of disease activity (ex-smoker, constant FEV1, no
frequent exacerbations, stable BMI and normal levels of poten-
tial biomarker(s) of disease activity). In this case, the physician
may need to optimise bronchodilator treatment, treat
comorbidities, and provide rehabilitation but may question the
need for anti-inﬂammatory therapy.
CONCLUSIONS
We propose an integrated way to address the complexity of
COPD: the ‘COPD control panel’. This proposal should be con-
sidered the starting point of a debate that, we hope, might
result in better clinical care of patients with COPD. We predict
that, in the near future, the availability of quick and cheap
‘omic’ analyses will add to the ‘control panel’, and that new
user-friendly bioinformatic technologies (so-called clinical deci-
sion support systems, which will be easily downloaded as
‘apps’)9 will allow the clinician to integrate this vast amount
of information for the beneﬁt of a single patient, hence fulﬁll-
ing the goal of ‘personalised’ medicine in COPD.
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